Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy doubled in the fourth quarter, but the Danish pharmaceutical giant warns that sales growth for all its drugs — including Ozempic — is expected to slow in the coming year.
Read more...
Read More Details
Finally We wish PressBee provided you with enough information of ( The Ozempic boom is slowing down )
Also on site :
- Canada’s Atlantic LNG Dreams Just Got Pricier
- Hisense erweitert ITS ConnectLife-Plattform auf Geräte von Drittanbietern über Home-APIs von Google
- H3C fait ses débuts au GITEX Europe avec la stratégie « Synergy+ » pour donner un nouvel élan à l'ère de l'IA